Elinzanetant (BAY3427080) + Placebo
Phase 3ActiveDevelopment Stage
Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes
Oct 14, 2022 โ Jun 5, 2028
About Elinzanetant (BAY3427080) + Placebo
Elinzanetant (BAY3427080) + Placebo is a phase 3 stage product being developed by Bayer for Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05587296. Target conditions include Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes.
Hype Score Breakdown
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05587296 | Phase 3 | Active |
| NCT05381142 | Phase 1 | Completed |
| NCT05099159 | Phase 3 | Completed |
| NCT05042362 | Phase 3 | Completed |
| NCT05030584 | Phase 3 | Completed |
| NCT04981431 | Phase 1 | Completed |
| NCT03596762 | Phase 2 | Completed |
Competing Products
20 competing products in Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer